Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2016 Sep 10;65(11):1411–1421. doi: 10.1007/s00262-016-1900-z

Figure 6. Proposed model by which TSA treatment enhances CD1d-mediated antigen presentation to NKT cells.

Figure 6

CD1d expression is enhanced following HDACi treatment, due, at least in part, to a dose-dependent increase in CD1d-cell surface expression. Treatment with HDACi results in a decrease in STAT3 as well as STAT3-inducible cytokine secretion by MCL cells. STAT3-inducible cytokines, such as IL-10, inhibit CD1d-mediated antigen presentation. Thus, HDACi treatment restores NKT cell responses through cell intrinsic and cell extrinsic mechanisms.